当前位置: X-MOL 学术Annu. Rev. Med. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Structure-Based Vaccine Antigen Design.
Annual Review of Medicine ( IF 10.5 ) Pub Date : 2019-01-27 , DOI: 10.1146/annurev-med-121217-094234
Barney S Graham 1 , Morgan S A Gilman 2 , Jason S McLellan 2
Affiliation  

Enabled by new approaches for rapid identification and selection of human monoclonal antibodies, atomic-level structural information for viral surface proteins, and capacity for precision engineering of protein immunogens and self-assembling nanoparticles, a new era of antigen design and display options has evolved. While HIV-1 vaccine development has been a driving force behind these technologies and concepts, clinical proof-of-concept for structure-based vaccine design may first be achieved for respiratory syncytial virus (RSV), where conformation-dependent access to neutralization-sensitive epitopes on the fusion glycoprotein determines the capacity to induce potent neutralizing activity. Success with RSV has motivated structure-based stabilization of other class I viral fusion proteins for use as immunogens and demonstrated the importance of structural information for developing vaccines against other viral pathogens, particularly difficult targets that have resisted prior vaccine development efforts. Solving viral surface protein structures also supports rapid vaccine antigen design and application of platform manufacturing approaches for emerging pathogens.

中文翻译:

基于结构的疫苗抗原设计。

通过快速鉴定和选择人类单克隆抗体的新方法,病毒表面蛋白的原子级结构信息以及蛋白免疫原和自组装纳米颗粒的精密工程设计能力,抗原设计和展示选择的新时代已经发展起来。尽管HIV-1疫苗的开发一直是这些技术和概念的推动力,但基于呼吸道合胞病毒(RSV)可能首先实现基于结构的疫苗设计的临床概念证明,其中构象依赖性获得对中和敏感的途径融合糖蛋白上的表位决定了诱导有效中和活性的能力。RSV的成功激发了其他I类病毒融合蛋白用作免疫原的基于结构的稳定作用,并证明了结构信息对于开发针对其他病毒病原体的疫苗的重要性,尤其是抵抗先前疫苗开发工作的困难目标。解决病毒表面蛋白结构也支持快速疫苗抗原设计和新兴病原体平台制造方法的应用。
更新日期:2019-01-28
down
wechat
bug